Philippe Fauchet, OBE, Venture Partner at 4BIO Capital, said: “LUCA Science has all the right ingredients to be an international success: it has the science, international team, and fantastic support from experienced investors. LUCA Science will use its platform technology to manufacture, store and deliver innovative mitochondrial drugs to research and development of therapeutics for unmet medical needs in a wide range of diseases for which there have been no effective treatments. LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs.